Cue Biopharma (CUE) FCF Margin (2018 - 2025)

Cue Biopharma has disclosed FCF Margin across 8 years of filings, most recently posting 11.33% for Q4 2025.

• FCF Margin for Q4 2025 came in at 11.33%, up 56164.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 145.53% (up 24636.0% YoY), and the FY2025 annual result was 79.6%, up 31229.0% from the prior year.
• FCF Margin came in at 11.33% for Q4 2025 at Cue Biopharma, up from 419.92% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 11.33% in Q4 2025 to a low of 49665.38% in Q2 2022.
• The 5-year median for FCF Margin is 573.0% (2024), against an average of 4068.52%.
• Across the five-year window, FCF Margin sank 4929948 bps in 2022 and surged 4891495 bps in 2023, its largest moves.
• Cue Biopharma's FCF Margin stood at 128.96% in 2021, then slumped by 5300 bps to 6963.58% in 2022, then soared by 91 bps to 601.76% in 2023, then increased by 5 bps to 572.97% in 2024, then soared by 98 bps to 11.33% in 2025.
• The last three FCF Margin figures came in at 11.33% (Q4 2025), 419.92% (Q3 2025), and 116.52% (Q2 2025), per Business Quant data.